AstraZeneca Looks To Insmed To Advance AZD7986 In Bronchiectasis
AstraZeneca has out-licensed a promising respiratory compound to Insmed Inc saying the US-based group is better placed to advance AZD7986 in bronchiectasis, a rare pulmonary disorder.
You may also be interested in...
AstraZeneca concludes week of four out-licensing transactions by selling US rights to Toprol XL to Aralez and ex-US rights to Rhinocort Aqua to J&J. Molecular Partners gets back rights to an IL-13/IL-17 inhibitor for pulmonary indications after a 2011 deal with Janssen unravels.
Continuing its strategy to exit non-core activities, AstraZeneca's licensed Allergan global rights to its IL-23 monoclonal antibody in Phase IIb testing for moderate-to-severe Crohn’s disease and ready for Phase II studies in ulcerative colitis. Analysts say the deal makes sense for both parties.
AstraZeneca’s Shaun Grady is an affable dealmaker whose talents – honed over three decades inside the group – are being put to the test as global business development head to help ensure Britain’s second-biggest drugmaker can successfully transform itself, its therapy focus and pipeline. He tells In Vivo about his role leading AZ’s transaction execution, due diligence and alliance and integration management, while overseeing its collaborative “externalization” program, licensing and partnering, M&A and divestments.